调查研究
Ma Xiuyun;Cai Haodong;Zheng Hong;Duan Ying
1999, 1(3): 154-159.
Objective: To observe prospectively the adverse reactions of a new drug, lamivudine, for hepatitis B. Methods: The adverse reactions were observed and both hematology and biochemical analyses were made in two groups, with lamivudine 100 mg a day and the other with starch tablet by random double blind placebo control clinical method for twelve weeks, and then the treatment followed for forty to one hundred and fifty-six weeks with lamivudine 100 mg a day. Results: During the double blind treatment period, no significant differences were shown in their incidence of the adverse reactions and hematology and biochemical indices. Some light adverse reactions were produced in patients, but with good tolerance in the open treatment period. The most patients' liver function was improved. However, more studies must be done on whether it is associated with a hyperlipidaemia or cardiovascular complications. Conclusion: Lamivudine is safe for hepatitis B. It has few adverse reactions and can be use...更多d for a long time with care of the blood lipid profile.
